← Eichor
Condition: Dmmr Colorectal Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Dmmr Colorectal Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Canc
Phase 1 · 1 location(s) · West China Hospital · NCT07076823DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With H
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05770102Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
Phase N/A · 5 location(s) · San Raffaele University · NCT06708429PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT05236972Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT03926338Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer
NA · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT04643041NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer
Phase 2 · 6 location(s) · University College, London · NCT05197322Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06903858A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT06686576SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cance
Phase N/A · 1 location(s) · Yunnan Cancer Hospital · NCT06477991KN035 for dMMR/MSI-H Advanced Solid Tumors
Phase 2 · 1 location(s) · 3D Medicines (Sichuan) Co., Ltd. · NCT03667170Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Me
Phase N/A · 20 location(s) · Federation Francophone de Cancerologie Digestive · NCT06353854Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer
Phase N/A · 1 location(s) · Xijing Hospital · NCT06613165Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT04636008Tislelizumab in People With Colorectal Cancer
Phase 2 · 3 location(s) · Memorial Sloan Kettering Cancer Center · NCT06529523Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
Phase 2 · 22 location(s) · UNICANCER · NCT06333314Familial Investigations of Childhood Cancer Predisposition
Phase N/A · 1 location(s) · St. Jude Children's Research Hospital · NCT03050268Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC
Phase 2 · 9 location(s) · GERCOR - Multidisciplinary Oncology Cooperative Group · NCT05310643A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 an
Phase 2 · 39 location(s) · Ono Pharmaceutical Co., Ltd. · NCT06948448Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or
Phase 2 · 5 location(s) · Emory University · NCT07140679A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369Immunotherapy in Patients With Early dMMR Rectal Cancer
Phase 2 · 5 location(s) · Odense University Hospital · NCT05732389FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 33 location(s) · Parabilis Medicines, Inc. · NCT05919264Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Col
Phase N/A · 2 location(s) · Geneplus-Beijing Co. Ltd. · NCT06098560A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer
Phase 1/Phase 2 · 22 location(s) · GlaxoSmithKline · NCT07213609Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT06520683Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/Phase 2 · 7 location(s) · Neonc Technologies, Inc. · NCT06047379Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
Phase 2 · 2 location(s) · University of Iowa · NCT05239546A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.